Cargando…

Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study

BACKGROUND: Endothelial dysfunction, largely dependent on impaired nitric oxide bioavailability, has been reportedly associated with incident type 2 diabetes. Our aim was to test the hypothesis that asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide formation, might be linke...

Descripción completa

Detalles Bibliográficos
Autores principales: Surdacki, Andrzej, Kruszelnicka, Olga, Rakowski, Tomasz, Jaźwińska-Kozuba, Aleksandra, Dubiel, Jacek S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642017/
https://www.ncbi.nlm.nih.gov/pubmed/23578341
http://dx.doi.org/10.1186/1475-2840-12-64
_version_ 1782268083119849472
author Surdacki, Andrzej
Kruszelnicka, Olga
Rakowski, Tomasz
Jaźwińska-Kozuba, Aleksandra
Dubiel, Jacek S
author_facet Surdacki, Andrzej
Kruszelnicka, Olga
Rakowski, Tomasz
Jaźwińska-Kozuba, Aleksandra
Dubiel, Jacek S
author_sort Surdacki, Andrzej
collection PubMed
description BACKGROUND: Endothelial dysfunction, largely dependent on impaired nitric oxide bioavailability, has been reportedly associated with incident type 2 diabetes. Our aim was to test the hypothesis that asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide formation, might be linked to future deterioration in glucose tolerance in stable coronary artery disease (CAD). METHODS: We studied 80 non-diabetic men (mean age 55 ± 11 years) with stable angina who underwent successful elective complex coronary angioplasty and were receiving a standard medication according to practice guidelines. Plasma ADMA and its structural isomer symmetric dimethylarginine (SDMA) were measured prior to coronary angiography. An estimate of insulin resistance by homeostasis model assessment (HOMA-IR index) was calculated from fasting insulin and glucose. Deterioration in glucose tolerance was defined as development of type 2 diabetes or progression from a normal glucose tolerance to impaired fasting glucose. RESULTS: Over a median follow-up of 55 months 11 subjects developed type 2 diabetes and 13 progressed to impaired fasting glucose. Incident deterioration of glucose tolerance was associated with ADMA (hazard ratio [HR] per 1-SD increment 1.64 [95% CI: 1.14–2.35]; P = 0.007), log (HOMA-IR index) (HR = 1.60 [1.16–2.20]; P = 0.004) and body-mass index (HR = 1.44 [0.95–2.17]; P = 0.08) by univariate Cox regression. ADMA (HR = 1.65 [1.14–2.38]; p = 0.008) and log (HOMA-IR index) (HR = 1.55 [1.10–2.17]; P = 0.01) were multivariate predictors of a decline in glucose tolerance. ADMA and SDMA were unrelated to body-mass index, HOMA-IR index, insulin or glucose. CONCLUSIONS: ADMA predicts future deterioration of glucose tolerance independently of baseline insulin resistance in men with stable CAD. Whether this association reflects a contribution of endothelial dysfunction to accelerated decline of insulin sensitivity, or represents only an epiphenomenon accompanying pre-diabetes, remains to be elucidated. The observed relationship might contribute to the well-recognized ability of ADMA to predict cardiovascular outcome.
format Online
Article
Text
id pubmed-3642017
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36420172013-05-03 Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study Surdacki, Andrzej Kruszelnicka, Olga Rakowski, Tomasz Jaźwińska-Kozuba, Aleksandra Dubiel, Jacek S Cardiovasc Diabetol Original Investigation BACKGROUND: Endothelial dysfunction, largely dependent on impaired nitric oxide bioavailability, has been reportedly associated with incident type 2 diabetes. Our aim was to test the hypothesis that asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide formation, might be linked to future deterioration in glucose tolerance in stable coronary artery disease (CAD). METHODS: We studied 80 non-diabetic men (mean age 55 ± 11 years) with stable angina who underwent successful elective complex coronary angioplasty and were receiving a standard medication according to practice guidelines. Plasma ADMA and its structural isomer symmetric dimethylarginine (SDMA) were measured prior to coronary angiography. An estimate of insulin resistance by homeostasis model assessment (HOMA-IR index) was calculated from fasting insulin and glucose. Deterioration in glucose tolerance was defined as development of type 2 diabetes or progression from a normal glucose tolerance to impaired fasting glucose. RESULTS: Over a median follow-up of 55 months 11 subjects developed type 2 diabetes and 13 progressed to impaired fasting glucose. Incident deterioration of glucose tolerance was associated with ADMA (hazard ratio [HR] per 1-SD increment 1.64 [95% CI: 1.14–2.35]; P = 0.007), log (HOMA-IR index) (HR = 1.60 [1.16–2.20]; P = 0.004) and body-mass index (HR = 1.44 [0.95–2.17]; P = 0.08) by univariate Cox regression. ADMA (HR = 1.65 [1.14–2.38]; p = 0.008) and log (HOMA-IR index) (HR = 1.55 [1.10–2.17]; P = 0.01) were multivariate predictors of a decline in glucose tolerance. ADMA and SDMA were unrelated to body-mass index, HOMA-IR index, insulin or glucose. CONCLUSIONS: ADMA predicts future deterioration of glucose tolerance independently of baseline insulin resistance in men with stable CAD. Whether this association reflects a contribution of endothelial dysfunction to accelerated decline of insulin sensitivity, or represents only an epiphenomenon accompanying pre-diabetes, remains to be elucidated. The observed relationship might contribute to the well-recognized ability of ADMA to predict cardiovascular outcome. BioMed Central 2013-04-11 /pmc/articles/PMC3642017/ /pubmed/23578341 http://dx.doi.org/10.1186/1475-2840-12-64 Text en Copyright © 2013 Surdacki et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Investigation
Surdacki, Andrzej
Kruszelnicka, Olga
Rakowski, Tomasz
Jaźwińska-Kozuba, Aleksandra
Dubiel, Jacek S
Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study
title Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study
title_full Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study
title_fullStr Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study
title_full_unstemmed Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study
title_short Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study
title_sort asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642017/
https://www.ncbi.nlm.nih.gov/pubmed/23578341
http://dx.doi.org/10.1186/1475-2840-12-64
work_keys_str_mv AT surdackiandrzej asymmetricdimethylargininepredictsdeclineofglucosetoleranceinmenwithstablecoronaryarterydiseasea45yearfollowupstudy
AT kruszelnickaolga asymmetricdimethylargininepredictsdeclineofglucosetoleranceinmenwithstablecoronaryarterydiseasea45yearfollowupstudy
AT rakowskitomasz asymmetricdimethylargininepredictsdeclineofglucosetoleranceinmenwithstablecoronaryarterydiseasea45yearfollowupstudy
AT jazwinskakozubaaleksandra asymmetricdimethylargininepredictsdeclineofglucosetoleranceinmenwithstablecoronaryarterydiseasea45yearfollowupstudy
AT dubieljaceks asymmetricdimethylargininepredictsdeclineofglucosetoleranceinmenwithstablecoronaryarterydiseasea45yearfollowupstudy